Liver-Expressed Antimicrobial Peptide 2 Is a Hepatokine That Predicts Weight Loss and Complete Remission of Type 2 Diabetes Mellitus after Vertical Sleeve Gastrectomy in Japanese Individuals
Authors:
- Hiroki NabekuraHNHiroki Nabekura
- Nurul IslamNINurul Islam
- Hideyuki SakodaHSHideyuki Sakoda
- Takashi YamaguchiTYTakashi Yamaguchi
- Atsuhito SaikiASAtsuhito Saiki
- Taiki NabekuraTNTaiki Nabekura
- Takashi OshiroTOTakashi Oshiro
- Yuri TanakaYTYuri Tanaka
- Shinya MurayamaSMShinya Murayama
- Weidong ZhangWZWeidong Zhang
- Ichiro TatsunoITIchiro Tatsuno
- Masamitsu NakazatoMNMasamitsu Nakazato
Open Access
- 24 April 2023
- journal article
- research article
- Published by S. Karger AG in Obesity Facts
- Vol. 16 (4) , 392-400
Abstract
Introduction: Vertical sleeve gastrectomy (VSG) is considered one of the most effective treatments for sustained weight loss and complete remission of type 2 diabetes mellitus (CR-T2DM). Liver-expressed antimicrobial peptide 2 (LEAP2), a ghrelin receptor antagonist peptide, is a metabolic hormone regulated by VSG. However, it is unknown whether LEAP2 can be used to predict the outcomes of VSG. This study aimed to evaluate LEAP2 as a predictive factor for weight loss and CR-T2DM after VSG. Methods: This retrospective study included 39 Japanese participants with obesity who underwent VSG. Serum LEAP2, des-acyl ghrelin (DAG), and other metabolic and anthropometric parameters were studied before and at 12 months after VSG. Receiver operating characteristics (ROC) curve was generated to evaluate predictive score for weight loss with cut-off value of >50 percent excess weight loss. ROC curve was also generated to assess CR-T2DM. Results: Serum LEAP2 levels were significantly higher in participants with body mass index (BMI) 32–50 kg/m2 than in those with normal weight. Participants with BMI >50 kg/m2 had lower serum LEAP2 concentrations than those with BMI 32–50 kg/m2. VSG caused a significant reduction in serum DAG concentrations, but it did not affect serum LEAP2 concentrations in either male or female participants. Preoperative serum LEAP2 concentration of 2.88 pmol/mL was the optimal cutoff value for predicting weight loss after VSG, with sensitivity of 80.0% and specificity of 75.9%. Preoperative serum LEAP2 level higher than 4.67 pmol/mL predicted CR-T2DM after VSG with sensitivity of 100% and specificity of 58.8%. Conclusion: Preoperative serum LEAP2 could predict weight loss and CR-T2DM as outcomes of VSG.Keywords
This publication has 30 references indexed in Scilit:
- Bariatric Surgery and Endoluminal Procedures: IFSO Worldwide Survey 2014Obesity Surgery, 2017
- Preoperative Prediction of Type 2 Diabetes Remission After Gastric Bypass Surgery: a Comparison of DiaRem Scores and ABCD ScoresObesity Surgery, 2016
- Standardized outcomes reporting in metabolic and bariatric surgerySurgery for Obesity and Related Diseases, 2015
- Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort studyThe Lancet Diabetes & Endocrinology, 2014
- Peripheral ghrelin transmits orexigenic signals through the noradrenergic pathway from the hindbrain to the hypothalamusCell Metabolism, 2006
- Porcine liver-expressed antimicrobial peptides, hepcidin and LEAP-2: cloning and induction by bacterial infectionDevelopmental & Comparative Immunology, 2006
- Induction of Cationic Chicken Liver-Expressed Antimicrobial Peptide 2 in Response to Salmonella enterica InfectionInfection and Immunity, 2004
- Isolation and biochemical characterization of LEAP‐2, a novel blood peptide expressed in the liverProtein Science, 2003
- A role for ghrelin in the central regulation of feedingNature, 2001
- Ghrelin is a growth-hormone-releasing acylated peptide from stomachNature, 1999